Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk (Q47145824)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 November 2017

Language	Label	Description	Also known as
English	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk	scientific article published on 2 November 2017

Statements

scholarly article

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk (English)

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

1 reference

based on heuristic

inferred from title

Hans-Jürgen Stellbrink

9

object named as

Hans-Jürgen Stellbrink

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Stéphane De Wit

13

object named as

Stephane De Wit

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

François Raffi

16

object named as

François Raffi

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

author name string

José M Gatell

1

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Lambert Assoumou

2

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Graeme Moyle

3

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Laura Waters

4

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Margaret Johnson

5

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Pere Domingo

6

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Julie Fox

7

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Esteban Martinez

8

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Giovanni Guaraldi

10

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Mar Masia

11

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Mark Gompels

12

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Eric Florence

14

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Stefan Esser

15

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Anton L Pozniak

17

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

NEAT022 Study Group*

18

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

language of work or name

0 references

publication date

2 November 2017

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

31

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

2503-2514

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

18

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Tolerability of integrase inhibitors in a real-life setting.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Psychiatric Symptoms in Patients Receiving Dolutegravir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

National Lipid Association Annual Summary of Clinical Lipidology 2016.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Backbones versus core agents in initial ART regimens: one game, two players.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Twenty years of boosting antiretroviral agents: where are we today?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Hit me with your best shot: dolutegravir - a space in the next WHO guidelines?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Will drug resistance against dolutegravir in initial therapy ever occur?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

What if HIV were unable to develop resistance against a new therapeutic agent?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Update of the drug resistance mutations in HIV-1: March 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case-control studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Tolerability of HIV integrase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

23 May 2018

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

15 August 2018

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5690310

1 December 2018

Intolerance of dolutegravir containing cART regimens in real life clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/29112070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAD.0000000000001675

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

release_4oobt2aedjdmbaojdn6nt2wkjy

1 reference

https://api.fatcat.wiki/v0/release/4oobt2aedjdmbaojdn6nt2wkjy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5690310

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47145824&oldid=2143011433"